作者
J1 De Kraker, N Graf, H Van Tinteren, F Pein, B Sandstedt, J Godzinski, MF Tournade
发表日期
2004/10/2
期刊
The Lancet
卷号
364
期号
9441
页码范围
1229-1235
出版商
Elsevier
简介
Background
Present treatment for Wilms' tumour is very successful. Now, efforts are aimed at reducing toxicity and burden of treatment by shortening schedules without loss of effectiveness. The objective of this randomised trial was to assess whether postoperative chemotherapy for patients with stage I intermediate-risk and anaplastic Wilms' tumour could be shortened to only 4 weeks from the standard 18 weeks, while maintaining equivalent event-free survival.
Methods
Between June, 1993, and June, 2000, 410 patients were randomly assigned after four doses of vincristine plus one course of dactinomycin postoperatively either to stop further adjuvant chemotherapy (no further chemotherapy group, n=200), or to receive a further two courses of the same chemotherapy (standard group, n=210). Previous treatment consisted of chemotherapy before nephrectomy of four doses of vincristine and two courses of …
引用总数
学术搜索中的文章
J De Kraker, N Graf, H Van Tinteren, F Pein… - The Lancet, 2004